Bank of America
JUNO

Bank of America’s Juno Therapeutics, Inc. JUNO Stock Holding History

Bank of America’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-104,449
Closed -$4.78M – 7551
2017
Q4 		$4.78M Buy
104,449
+37,439
+56% +$1.87M ﹤0.01% 3166
2017
Q3 		$3.01M Buy
67,010
+19,982
+42% +$681K ﹤0.01% 3644
2017
Q2 		$1.41M Buy
47,028
+7,856
+20% +$194K ﹤0.01% 4185
2017
Q1 		$870K Sell
39,172
-13,970
-26% -$300K ﹤0.01% 4518
2016
Q4 		$1M Buy
53,142
+36,837
+226% +$901K ﹤0.01% 4340
2016
Q3 		$489K Sell
16,305
-22,711
-58% -$707K ﹤0.01% 4636
2016
Q2 		$1.5M Buy
39,016
+14,159
+57% +$588K ﹤0.01% 3860
2016
Q1 		$947K Sell
24,857
-31,941
-56% -$1.11M ﹤0.01% 4147
2015
Q4 		$2.5M Buy
56,798
+26,061
+85% +$1.29M ﹤0.01% 3605
2015
Q3 		$1.25M Sell
30,737
-7,041
-19% -$309K ﹤0.01% 4163
2015
Q2 		$2.01M Buy
37,778
+33,883
+870% +$1.8M ﹤0.01% 3450
2015
Q1 		$236K Buy
3,895
+1,895
+95% +$92K ﹤0.01% 4823
2014
Q4 		$104K Buy
+2,000
New +$89.5K ﹤0.01% 5858

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Bank of America's JUNO Position: Q1 2018 in Review

Bank of America sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 104,449 shares — an estimated $4.78M sold.

Bank of America first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $4.78M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Bank of America reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Bank of America sold 104,449 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $4.78M.
  • Bank of America first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • Bank of America's Juno Therapeutics, Inc. position peaked at $4.78M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Bank of America's 13F filing for Q1 2018, filed 15 May 2018.